Cargando…
Vaccine delivery using nanoparticles
Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evok...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607064/ https://www.ncbi.nlm.nih.gov/pubmed/23532930 http://dx.doi.org/10.3389/fcimb.2013.00013 |
_version_ | 1782264073713352704 |
---|---|
author | Gregory, Anthony E. Titball, Richard Williamson, Diane |
author_facet | Gregory, Anthony E. Titball, Richard Williamson, Diane |
author_sort | Gregory, Anthony E. |
collection | PubMed |
description | Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens. |
format | Online Article Text |
id | pubmed-3607064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-36070642013-03-25 Vaccine delivery using nanoparticles Gregory, Anthony E. Titball, Richard Williamson, Diane Front Cell Infect Microbiol Microbiology Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens. Frontiers Media S.A. 2013-03-25 /pmc/articles/PMC3607064/ /pubmed/23532930 http://dx.doi.org/10.3389/fcimb.2013.00013 Text en Copyright © 2013 Gregory, Titball and Williamson. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. |
spellingShingle | Microbiology Gregory, Anthony E. Titball, Richard Williamson, Diane Vaccine delivery using nanoparticles |
title | Vaccine delivery using nanoparticles |
title_full | Vaccine delivery using nanoparticles |
title_fullStr | Vaccine delivery using nanoparticles |
title_full_unstemmed | Vaccine delivery using nanoparticles |
title_short | Vaccine delivery using nanoparticles |
title_sort | vaccine delivery using nanoparticles |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607064/ https://www.ncbi.nlm.nih.gov/pubmed/23532930 http://dx.doi.org/10.3389/fcimb.2013.00013 |
work_keys_str_mv | AT gregoryanthonye vaccinedeliveryusingnanoparticles AT titballrichard vaccinedeliveryusingnanoparticles AT williamsondiane vaccinedeliveryusingnanoparticles |